Pair Name	Shikonin, Cisplatin
Disease Info	[ICD-11: 2C94.Z]	Bladder cancer		Investigative
Biological Phenomena	Induction-->ROS generation; Induction--> Loss of mitochondrial membrane potential
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Activity	CASP3	hsa836
	Up-regulation	Activity	CASP9	hsa842
In Vitro Model	HCT 116	Colon carcinoma	Homo sapiens (Human)	CVCL_0291
	HT-29	Colon adenocarcinoma	Homo sapiens (Human)	CVCL_0320
	SW620	Colon adenocarcinoma	Homo sapiens (Human)	CVCL_0547
	NCM460	Healthy	Homo sapiens (Human)	CVCL_0460
In Vivo Model	HCT116 cells (5×10⁶ cells in 100uL of PBS) were harvested and injected subcutaneously into the right flank of five-week-old athymic BALB/cA nu/nu female mice
Result	Shikonin as a synergistic agent to cisplatin could be a highly efficient way to achieve anticancer synergism by inducing intracellular oxidative stress

Pair Name	Shikonin, Cisplatin
Disease Info	[ICD-11: 2C73]	Ovarian cancer		Investigative
Biological Phenomena	Induction-->Ferroptosis
Gene Regulation	Down-regulation	Expression	GPX4	hsa2879
	Up-regulation	Expression	HMOX1	hsa3162
In Vitro Model	A2780/CDDP	Ovarian endometrioid adenocarcinoma	Homo sapiens (Human)	CVCL_D619
In Vivo Model	A total of 4×10⁶ A2780/DDP cells were suspended in 200 μl of PBS and injected subcutaneously into the right flank of each mouse.
Result	Shikonin and cisplatin synergistically overcome cisplatin resistance of ovarian cancer by inducing ferroptosis via upregulation of HMOX1 to promote Fe2+ accumulation